CAR T-cell cancer therapies: do not forget the heart.

Graph: Graphical Abstract The registry data presented by Mahmood et al.9 demonstrate that CAR T-cell recipients experience severe cardiac events (SCEs) at significant rates. Adoptive T-cell transfer therapies represent a therapeutic option with high initial response rates for an increasing spectrum of patients. [Extracted from the article]